Pharmaceutical Testing and Development
Block1 Icon

PDX Models

StemMed provides state-of-the-art pre-clinical drug testing services using a large panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers. Breast cancer PDX models were developed from an ethnically diverse patient population, and represent all clinically-defined subtypes, including estrogen receptor positive (ER+), HER2+, and “triple-negative” cancers.


StemMed has extensive experience in performing in vivo drug testing assays using PDX models. All studies are custom designed to meet your experimental goals, and can range from dose-response assays in a single PDX, to full scale animal clinical trials in 20 or more PDX.


StemMed has IND and IRB approval to start first-in-human studies October 2017 at MD Anderson of C188-9, its oral inhibitor of signal transducer and activator of transcription 3 (STAT3), for targeted therapy in patients with solid tumors, including triple-negative breast cancer, hepatocellular carcinoma, head and neck squamous cell cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, and melanoma (for more details, see NIH link: StemMed also is performing 14-week, GLP-compliant studies of C188-9 to enable testing for safety and effectiveness in patients with cachexia secondary to cancer or chromic kidney disease, idiopathic pulmonary fibrosis, scleroderma, inflammatory bowel disease, asthma, and immediate-type hypersensitivity reactions.